查看“Amatuximab”的源代码

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

    <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
        <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
            <strong>[[Amatuximab]]</strong>（研发代码：<strong>[[MORAb-009]]**）是一种针对**[[间皮素]]</strong>（Mesothelin,<strong>[[MSLN]]**）的人鼠嵌合型**[[IgG1]]**单克隆抗体。该药物由**[[Morphotek]]**公司利用其专有的**[[Libraderm]]**技术平台开发，旨在通过高亲和力结合并阻断**[[间皮素]]**与**[[CA125]]**的相互作用，从而抑制肿瘤细胞的粘附与转移。**[[Amatuximab]]**是首个进入临床研究的针对**[[MSLN]]**靶点的抗体药物，已被**[[FDA]]**和**[[EMA]]**授予用于治疗**[[恶性间皮瘤]]**的**[[孤儿药认定]]**。目前，其临床探索主要集中于联合化疗治疗**[[间皮瘤]]**、**[[胰腺癌]]**及**[[卵巢癌]]**等高表达间皮素的实体瘤。
        </p>
    </div>

    <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">
        
        <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #ffffff 100%); text-align: center; cursor: pointer;">
            <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">Amatuximab(MORAb-009)</div>
            <div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">抗MSLN单抗·孤儿药认定·点击展开</div>
        </div>
        
        <div class="mw-collapsible-content">
            <div style="padding: 20px; text-align: center; background-color: #f8fafc;">
                <div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 15px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);">
                     <div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Chimeric mAb:Targeting Glycosylphosphatidylinositol-anchored MSLN</div>
                </div>
                <div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶标：<strong>[[MSLN]]</strong>(间皮素)</div>
            </div>

            <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;"><strong>[[Entrez]]</strong>ID</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">10232(<strong>[[MSLN]]</strong>)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">人鼠嵌合单克隆抗体</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约147kDa</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">同位素</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">IgG1 kappa</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">研发厂家</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;"><strong>[[Eisai]]</strong>/Morphotek</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">研究状态</th>
                    <td style="padding: 12px; color: #f59e0b;">临床II期</td>
                </tr>
            </table>
        </div>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">药理机制：阻断粘附与免疫介导杀伤</h2>
    
    <p style="margin: 15px 0; text-align: justify;">
        <strong>[[Amatuximab]]</strong>的作用机制主要基于对肿瘤生物学行为的干预及对机体免疫系统的动员：
    </p>
    
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;">阻断受体-配体结合：<strong>[[间皮素]]</strong>通常与粘蛋白<strong>[[CA125]]</strong>（MUC16）结合，介导肿瘤细胞的异型粘附，这是间皮瘤和卵巢癌发生腹膜转移的关键。Amatuximab通过特异性结合<strong>[[MSLN]]</strong>，竞争性抑制其与<strong>[[CA125]]</strong>的结合，从而削弱肿瘤的扩散能力。</li>
        <li style="margin-bottom: 12px;">介导ADCC效应：作为<strong>[[IgG1]]</strong>型抗体，该药物的<strong>[[Fc段]]</strong>可招募<strong>[[NK细胞]]</strong>及巨噬细胞，通过<strong>[[抗体依赖性细胞毒性]]</strong>（ADCC）直接溶解并杀伤肿瘤细胞。</li>
        <li style="margin-bottom: 12px;">抑制信号转导：初步研究显示，该抗体结合后可能诱导间皮素的内吞，进而干扰与其相关的下游细胞增殖信号。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床评价：间皮瘤与多瘤种研究矩阵</h2>

    <div style="overflow-x: auto; margin: 30px auto; max-width: 90%;">
        <table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;">
            <tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">临床研究项目</th>
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">目标患者群体</th>
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">关键发现/终点</th>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[FOCUS]] 研究</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">初治<strong>[[恶性胸膜间皮瘤]]</strong>(MPM)。</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">联合<strong>[[培美曲塞]]</strong>/顺铂。中位OS达14.8个月，在特定亚组中显示出较好的获益趋势。</td>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[NCT00570713]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">复发难治性<strong>[[胰腺癌]]</strong>。</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">评估单药安全性，显示出良好的耐受性，但在末线患者中单药响应率有限。</td>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">安全性特征</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;" colspan="2;">主要不良反应为输注相关反应(IRR)、疲劳、恶心及一过性转氨酶升高。未观察到明显的肺毒性。</td>
            </tr>
        </table>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：基于靶标丰度的筛选与联合应用</h2>
    <p style="margin: 15px 0; text-align: justify;">
        <strong>[[Amatuximab]]</strong>的临床开发重点正逐步向精准筛选与多药联合模式演进：
    </p>
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;">受体表达分层：鉴于<strong>[[MSLN]]</strong>表达密度的不均一性，临床上常通过<strong>[[免疫组化]]</strong>（IHC）评估蛋白水平。对于“强阳性”患者，Amatuximab阻断粘附的效能更为显著。</li>
        <li style="margin-bottom: 12px;">化疗协同效应：该抗体常被作为标准一线化疗（培美曲塞+顺铂）的附加疗法。通过化疗诱导肿瘤坏死并释放更多抗原，Amatuximab可进一步强化<strong>[[ADCC]]</strong>反应。</li>
        <li style="margin-bottom: 12px;">耐药挽救思考：针对<strong>[[Anetumab ravtansine]]</strong>（MSLN-ADC）耐药后的患者，使用非载荷型抗体Amatuximab是否存在二线获益仍是目前的学术争论点。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2>
    <div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;">
        <ul style="margin: 0; padding-left: 20px; color: #334155;">
            <li style="margin-bottom: 8px;"><strong>[[间皮素]]</strong>(MSLN)：定位于细胞膜表面的糖蛋白，是间皮瘤最关键的生物标志物。</li>
            <li style="margin-bottom: 8px;"><strong>[[Anetumab ravtansine]]</strong>：基于相同靶点开发的<strong>[[ADC]]</strong>药物，是Amatuximab在管线竞争中的重要对手。</li>
            <li style="margin-bottom: 8px;"><strong>[[CA125]]</strong>：卵巢癌常用标志物，也是Amatuximab试图阻断的配体。</li>
            <li style="margin-bottom: 8px;"><strong>[[Morphotek]]</strong>：一家专注于通过蛋白工程改善抗体结合性能的生物技术公司。</li>
        </ul>
    </div>

    <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
        <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span>
        
        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [1] <strong>Hassan R, et al. (2014).</strong> <em>Amatuximab and Pemetrexed/Cisplatin in Patients with Unresectable Malignant Pleural Mesothelioma: A Multicenter Phase II Study.</em> <strong>[[The Lancet Oncology]]</strong>.<br>
            <span style="color: #475569;">[权威点评]：该项FOCUS研究确立了Amatuximab在MPM一线治疗中的安全性及初步临床获益空间。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [2] <strong>Alewine C, et al. (2014).</strong> <em>Mesothelin-targeted therapies in cancer: An update.</em> <strong>[[The Oncologist]]</strong>.[Academic Review]<br>
            <span style="color: #475569;">[学术点评]：总结了从裸抗(Amatuximab)到ADC及CAR-T在间皮素靶点开发中的技术更迭逻辑。</span>
        </p>
    </div>

    <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
        <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
            Amatuximab(MSLN单抗)研发生态·知识图谱
        </div>
        <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td>
                <td style="padding: 10px 15px; color: #334155;"><strong>[[MSLN]]</strong>•<strong>[[CA125]]</strong>•<strong>[[MUC16]]</strong>•<strong>[[GPI]]</strong>•<strong>[[CD16A]]</strong></td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">同类管线</td>
                <td style="padding: 10px 15px; color: #334155;"><strong>[[Anetumab ravtansine]]</strong>•<strong>[[RC88]]</strong>•<strong>[[BMS-986148]]</strong>•<strong>[[LMB-100]]</strong></td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td>
                <td style="padding: 10px 15px; color: #334155;"><strong>[[Eisai]]</strong>•<strong>[[Morphotek]]</strong>•<strong>[[FDA]]</strong>•<strong>[[ASCO]]</strong>•<strong>[[ESMO]]</strong></td>
            </tr>
            <tr>
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">前沿探索</td>
                <td style="padding: 10px 15px; color: #334155;"><strong>[[联合PD-1二线治疗研究]]</strong>•<strong>[[基于MSLN表达量预测生物标志物]]</strong>•<strong>[[腹膜转移控制模型评估]]</strong>•<strong>[[与铂类化疗减毒协同研究]]</strong></td>
            </tr>
        </table>
    </div>

</div>